Global Cannabis Business Leaders, Scientists, Technologists & Thought Leaders Gather For CannaTech Cape Town, South Africa, November 24 – 26, 2019

ISRAEL: As the global medical cannabis market continues to expand and increasing numbers of countries around the globe legalize its use, the renowned CannaTech Summit will take place for the first time on the African Continent in Cape Town, South Africa, November 24 – 26 at The Lookout, V&A Waterfront.

With estimates that the cannabis and associated products market could be worth R27 billion by 2023, this immense potential has led to a boom in regional cannabis interest and investment.

CannaTech Cape Town will bring together industry leaders from across the African Continent and around the world known for their significant and ground-breaking contributions to the global medical and recreational cannabis market in all fields including Agricultural Tech and Innovation, Business and Finance, Policy and Regulation, Science and Medicine.

“The global interest in Africa’s cannabis market and South Africa’s recent legislative acceptance of cannabis makes Cape Town the perfect destination for CannaTech. Following South Africa, several African countries, including Swaziland, Malawi, and Zimbabwe, are examining legalizing cannabis cultivation for medical or industrial applications.  We are thrilled to bring some of the world’s leading companies and investors to CapeTown to meet with their counterparts to discuss a range of business and technological issues and work with like minded professionals who understand the immense global health and business potential of medical and recreational cannabis moving forward,” said Saul Kaye, Founder and CEO of iCAN:Israel-Cannabis. “As someone born in South Africa, I am especially looking forward to establishing ties throughout the entire continental cannabis eco-system,” he added.

Halo Labs Announces Strategic Partnership In Lesotho Africa

LESOTHO: Halo Labs announced it has signed a letter of intent to enter into a partnership with Bophelo Bioscience and Wellness Pty Ltd, a Lesotho based cannabis company. Halo will provide management services and expertise to build, design and operate cGAP cultivation and cGMP extraction facilities in exchange for a 20% equity position in Bophelo Bioscience, as well as a royalty on future extracted products. The Company has also entered into an off-take agreement whereby Halo will acquire all of Bophelo Bioscience’s production at prevailing market rates at time of production.

Screenshot 2018-12-14 07.57.35Bophelo Bioscience is the holder of one of a limited number of licenses in Lesotho to import, cultivate, manufacture and export cannabis products. Bophelo Bioscience also holds a 98-year lease over a 14 hectare land package with an option on an additional 194 hectares. Bophelo Bioscience expects to establish a 5 hectare greenhouse facility in the first quarter of 2019, which they will use to cultivate high quality, low cost cannabis products for extraction and export to international markets. Bophelo Bioscience’s site is located near the town of T’sakholo; which is approximately 70 km south of Maseru, Lesotho’s capital city. The site has good soil conditions, access to an abundant and naturally occurring pure water supply, as well as access to cheap electricity. To service the large scale grow operation will be a full cannabis extraction facility capable of producing over 4 million grams of concentrates and oils per year.

Lesotho was the first African country to legalize the cultivation and manufacturing of cannabis and has attracted international investments from major cannabis companies such as Canopy, Aphria and Supreme. Lesotho is a small, mountainous, high altitude country entirely landlocked by South Africa, with a temperate, low humidity climate boasting an abundance of sunshine, clean air and pristine spring water; all of which provide ideal conditions for greenhouse cultivation. First cannabis was exported from Lesotho in early 2018 and the Lesotho government has indicated that outdoor cultivation may be permitted from 2019, while the outdoor cultivation of hemp is already permitted. Lesotho has international trade agreements with over 30 countries including Canada, United Kingdom, Australian and the EU and has low tax structure of 10% with full deductibility of expenses.

Kiran Sidhu, CEO and Director for Halo comments: “We are very excited to partner with Bophelo Bioscience as they have the largest land package in Lesotho, which has an ideal environment to grow low cost cannabis which can be extracted into high quality oils and concentrates to be sold internationally. As the global cannabis market continues to mature and open up around the world, having a cGMP facility in Lesotho with abundant cGAP extractable cannabis will provide Halo with a competitive advantage to serve international markets, including Europe.”

South Africa: Highest Court Upholds Right To Consume Marijuana In Private

SOUTH AFRICA: The nation’s highest court has upheld a 2017 decision finding that the use of marijuana by adults in private is constitutionally protected behavior.

Judges unanimously ruled that privacy protections encompass an adult’s right to possess and grow cannabis in a private space. It is not “a criminal offense for an adult to use or be in possession of cannabis in private for his or her personal consumption,” the court determined.

Public cannabis use and marijuana sales remain prohibited under the ruling.

South African politicians first outlawed marijuana in 1908. Annually, some 13 percent of all arrests in the nation are marijuana-related.

For more information, contact Paul Armentano, NORML Deputy Director, at: or NORML Political Director, Justin Strekal, at (202) 483-5500.

Tilray Exports Medical Cannabis To South Africa

First-ever export of plant-derived cannabinoid product to the continent of Africa

CANADA: Tilray, a global pioneer in cannabis cultivation, processing and distribution, today announced that it has successfully exported medical cannabis products to South Africa for nationwide distribution to qualified patients through pharmacies. Tilray’s product is the first cannabinoid-based product derived from the cannabis plant that has ever been legally exported to and made available for medical purposes in the country of South Africa and on the continent of Africa.

“With this announcement, Tilray products are now available in nine countries on five continents. This export is another strategic milestone as we aim to build the world’s leading medical cannabis brand,” said Brendan Kennedy, Tilray CEO. “We are encouraged by the evolving regulations pertaining to cannabis in South Africa and around the world and are pleased to make our pharmaceutical-grade products available to qualified patients in need in throughout the country.”

Tilray’s medical cannabis product in South Africa is a GMP-manufactured, full-spectrum oral solution featuring a balanced ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD). The product is available to qualified patients under South Africa’s named patient program. Through that program, authorized practitioners can apply for permission to access and prescribe unregistered medicines, including the Tilray product, when intending to treat individual patients for specific conditions where certain registered medicines have failed. The product will then be distributed to patients through authorized distribution channels.


South Africa Parliament Introduces Bill To Legalize Dagga

SOUTH AFRICA: The Medical Innovation Bill, a bill to legalize Cannabis in South Africa for medical, economic and industrial purposes, was introduced in parliament today.

The bill was submitted by Member of Parliament, Mario GR Oriani-Ambrosini from the Inkatha Freedom Party. The Medical Innovation Bill aims to make provision for innovations in medical treatments by legalizing the use of cannabis for medical, economic and industrial purposes.

Last year Oriani-Ambrosini was diagnosed with stage four, inoperable lung cancer, which forms the background to this bill. People with life-threatening diseases such as cancer are legally denied access to a medicine that they could be growing themselves. Under current legislation, medical practitioners are legally denied the right to prescribe proven to be effective and harmless medication to their patients, which includes cannabis, on the basis that it hasn’t been approved in terms of the legally required double blind clinical studies.